Pennsylvania-based AI drug development company Generate Biomedicines has entered into a USD 1.9 billion worth multi-target, multimodality research collaboration with US biotechnology company Amgen to discover and develop protein therapeutics.
The duo will initially work on developing five clinical targets across various therapeutic areas and modalities, and will also have the option to collaborate on an additional five programs later on. The partnership will leverage Generate’s AI technology and wet lab capabilities as well as Amgen’s protein engineering expertise.
Generate will receive an upfront payment of USD 50 million for the first five programs, followed by up to USD 370 million in additional milestones and royalty payments for each project, totaling USD 1.9 billion. Amgen will also participate in one of Generate’s future financing rounds—the most recent one being a USD 370 million Series B round in November 2021.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.